Ultrasound Findings in Diabetic Pregnancies

Description

The goal of our study is to identify ultrasonographic markers that can predict adverse neonatal outcomes. Specifically, we hypothesize that an increase in fetal liver volumes will increase transcutaneous bilirubin (TcB) in the newborn and thus jaundice requiring phototherapy. This information can be used in patient counseling and to guide future screening protocols for ultrasound in individuals with diabetes.

Conditions

Diabetes

Study Overview

Study Details

Study overview

The goal of our study is to identify ultrasonographic markers that can predict adverse neonatal outcomes. Specifically, we hypothesize that an increase in fetal liver volumes will increase transcutaneous bilirubin (TcB) in the newborn and thus jaundice requiring phototherapy. This information can be used in patient counseling and to guide future screening protocols for ultrasound in individuals with diabetes.

Ultrasound Findings Predictive of Neonatal Outcomes in Diabetic Pregnancies

Ultrasound Findings in Diabetic Pregnancies

Condition
Diabetes
Intervention / Treatment

-

Contacts and Locations

Norfolk

Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Eastern Virginia Medical School, Norfolk, Virginia, United States, 23507

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients who enter pregnancy with a diagnosis of type I or type II diabetes mellitus.
  • * Pregnant women between the ages of 18-45
  • * Live, singleton gestation
  • * Understanding and ability to give informed consent
  • * Patient unwilling or unable to provide consent
  • * Intrauterine fetal demise (no fetal heart beat identified and documented by two physicians)
  • * Age less than 18 years of age
  • * Multifetal gestation
  • * Chromosomal abnormality
  • * Congenital infection (Toxoplasmosis, Cytomegalovirus, Rubella, Varicella Zoster, Parvovirus B19
  • * Major fetal congenital malformations (such as: major congenital heart defect, omphalocele, open neural tube defect, etc)

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eastern Virginia Medical School,

Study Record Dates

2025-06-01